These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 19070811)

  • 1. [The natural history of metastatic prostate cancer].
    Lebret T; Méjean A
    Prog Urol; 2008 Nov; 18 Suppl 7():S327-31. PubMed ID: 19070811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.
    Park YH; Hwang IS; Jeong CW; Kim HH; Lee SE; Kwak C
    J Urol; 2009 Jun; 181(6):2520-4; discussion 2525. PubMed ID: 19371894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [PSA kinetics after total prostatectomy].
    Riedinger JM; Eche N; Fulla Y; Thuillier F
    Ann Biol Clin (Paris); 2009; 67(1):39-46. PubMed ID: 19189884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer.
    Gleave M; Klotz L; Taneja SS
    Urol Oncol; 2009; 27(1):81-6. PubMed ID: 19111804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
    Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
    Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Group IIA phospholipase A as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality.
    Mirtti T; Laine VJ; Hiekkanen H; Hurme S; Rowe O; Nevalainen TJ; Kallajoki M; Alanen K
    APMIS; 2009 Mar; 117(3):151-61. PubMed ID: 19245588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New molecular biomarkers for the prognosis and management of prostate cancer--the post PSA era.
    Bickers B; Aukim-Hastie C
    Anticancer Res; 2009 Aug; 29(8):3289-98. PubMed ID: 19661347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications.
    Shah RB; Chinnaiyan AM
    Adv Anat Pathol; 2009 May; 16(3):145-53. PubMed ID: 19395877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of hormonotherapy in the treatment of metastatic prostate cancer].
    Lebret T; Méjean A
    Prog Urol; 2008 Nov; 18 Suppl 7():S332-7. PubMed ID: 19070812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proposed substages for metastatic prostate cancer.
    Crawford ED; Blumenstein BA
    Urology; 1997 Dec; 50(6):1027-8. PubMed ID: 9426745
    [No Abstract]   [Full Text] [Related]  

  • 11. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure.
    Blana A; Brown SC; Chaussy C; Conti GN; Eastham JA; Ganzer R; Murat FJ; Pasticier G; Rebillard X; Rewcastle JC; Robertson CN; Thuroff S; Ward JF
    BJU Int; 2009 Oct; 104(8):1058-62. PubMed ID: 19388986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer?
    Tareen B; Godoy G; Sankin A; Temkin S; Lepor H; Taneja SS
    BJU Int; 2009 Jul; 104(2):195-9. PubMed ID: 19191784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel model of bone-metastatic prostate cancer in immunocompetent mice.
    Power CA; Pwint H; Chan J; Cho J; Yu Y; Walsh W; Russell PJ
    Prostate; 2009 Nov; 69(15):1613-23. PubMed ID: 19585491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer.
    Darnel AD; Behmoaram E; Vollmer RT; Corcos J; Bijian K; Sircar K; Su J; Jiao J; Alaoui-Jamali MA; Bismar TA
    Clin Cancer Res; 2009 Feb; 15(4):1376-83. PubMed ID: 19228738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression of Smad4 in prostate cancer LNCaP and ARCaP cell lines with different metastatic potentials and its significance].
    Wu KJ; Zhang D; Zhu GF; Cheng HP; Zeng J; Zhang LL; Wang XY; He DL
    Zhonghua Nan Ke Xue; 2009 Jan; 15(1):41-4. PubMed ID: 19288748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z; Liu J; Li S; Shen W
    Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer.
    Schröder FH; Roobol MJ
    Curr Opin Urol; 2009 May; 19(3):227-31. PubMed ID: 19357513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proposed update on substaging metastatic prostate cancer.
    Crawford ED; Connor T
    Urology; 2009 Jul; 74(1):237. PubMed ID: 19567307
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy.
    Stock RG; Klein TJ; Cesaretti JA; Stone NN
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):753-8. PubMed ID: 19084351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
    Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.